Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 5, 2016, Pages 1027-1036

  Robert, Jérôme ^a   Stukas, Sophie ^a   Button, Emily ^a   Cheng, Wai Hang ^a   Lee, Michael ^a   Fan, Jianjia ^a   Wilkinson, Anna ^a   Kulic, Iva ^a   Wright, Samuel D ^b   Wellington, Cheryl L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CSL LIMITED   (Australia)

Author keywords

ABCA1; Alzheimer's disease; Amyloid beta; ApoA I; Reconstituted HDL

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HISTOLOGY; IN VITRO STUDY; LIVER; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 84951320436     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.10.005     Document Type: Article

References (67)

1. Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013, 80:1778-1783.
2. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (New York, N.Y.) 2002, 297:353-356.
3. Snyder H.M., et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 2014, 1-8. 10.1016/j.jalz.2014.10.008.
4. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm. 2002, 109:813-836.
5. Zipfel G.J., Han H., Ford A.L., Lee J.M. Cerebral amyloid angiopathy: progressive disruption of the neurovascular unit. Stroke 2009, 40:S16-S19.
6. Pontes-Neto O.M., Auriel E., Greenberg S.M. Advances in our understanding of the pathophysiology, detection and management of cerebral amyloid angiopathy. Eur Neurol. Rev. 2012, 7:134-139.
7. Arvanitakis Z., Leurgans S.E., Barnes L.L., Bennett D.A., Schneider J.A. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011, 42:722-727.
8. Smith E.E., Schneider J.A., Wardlaw J.M., Greenberg S.M. Cerebral microinfarcts: the invisible lesions. Lancet Neurol. 2012, 11:272-282.
9. Launer L.J., White L.R., Petrovitch H., Ross G.W., Curb J.D. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001, 57:1447-1452.
10. Launer L.J., et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 2000, 21:49-55.
11. Kivipelto M., et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 2005, 62:1556-1560.
12. Whitmer R.A., et al. Central obesity and increased risk of dementia more than three decades later. Neurology 2008, 71:1057-1064.
13. Wu W., et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann. Neurol. 2008, 64:698-706.
14. Fitzpatrick A.L., et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 2009, 66:336-342.
15. Pendlebury S.T., Rothwell P.M. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009, 8:1006-1018.
16. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 2009, 28:75-80.
17. Ahtiluoto S., et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010, 75:1195-1202.
18. Raji C.A., et al. Brain structure and obesity. Hum. Brain Mapp. 2010, 31:353-364.
19. Cheng D., et al. Type 2 diabetes and late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2011, 31:424-430.
20. Debette S., et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011, 77:461-468.
21. Ninomiya T., et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension 2011, 58:22-28.
22. Ohara T., et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 2011, 77:1126-1134.
23. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011, 7:137-152.
24. Rönnemaa E., Zethelius B., Lannfelt L., Kilander L. Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement. Geriatr. Cogn. Disord. 2011, 31:460-466.
25. Rusanen M., Kivipelto M., Quesenberry C.P., Zhou J., Whitmer R.A. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch. Intern. Med. 2011, 171:333-339.
26. Xu W.L., et al. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011, 76:1568-1574.
27. Luchsinger J.A., Cheng D., Tang M.X., Schupf N., Mayeux R. Central obesity in the elderly is related to late-onset Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2012, 26:101-105.
28. Mineo C., Shaul P.W. Regulation of signal transduction by HDL. J. Lipid Res. 2013, 54:2315-2324.
29. Rosenson R.S., et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012, 125:1905-1919.
30. Riwanto M., Landmesser U. High-density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J. Lipid Res. 2013, 10.1194/jlr.R037762.
31. Brunham L.R., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 2006, 116:1052-1062.
32. Pitas R.E., Boyles J.K., Lee S.H., Hui D., Weisgraber K.H. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 1987, 262:14352-14360.
33. Chiba H., et al. Effects of triamcinolone on brain and cerebrospinal fluid apolipoprotein E levels in rats. Life Sci. 1997, 60:1757-1761.
34. Saito K., et al. Marked increases in concentrations of apolipoprotein in the cerebrospinal fluid of poliovirus-infected macaques: relations between apolipoprotein concentrations and severity of brain injury. Biochem. J. 1997, 321(Pt 1):145-149.
35. Song H., et al. Cerebrospinal fluid apo E and apo a-I concentrations in early- and late-onset Alzheimer's disease. Neurosci. Lett. 1997, 231:175-178.
36. Song H., et al. Apo A-I and apo E concentrations in cerebrospinal fluids of patients with acute meningitis. Ann. Clin. Biochem. 1998, 35(Pt 3):408-414.
37. Demeester N., et al. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J. Lipid Res. 2000, 41:963-974.
38. Fukuyama R., et al. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease. Eur. Neurol. 2000, 43:161-169.
39. Koch S., et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 2001, 42:1143-1151.
40. Roher A.E., et al. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009, 14:493-501.
41. Stukas S., et al. Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. J. Am. Heart Assoc. 2014, 3.
42. Merched A., Xia Y., Visvikis S., Serot J.M., Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 2000, 21:27-30.
43. Shih Y.-H., et al. Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer's Disease. J. Alzheimers Dis. 2014, 1-11. 10.3233/JAD-140111.
44. Saczynski J.S., White L., Peila R.L., Rodriguez B.L., Launer L.J. The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am. J. Epidemiol. 2007, 165:985-992.
45. Reitz C., et al. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch. Neurol. 2010, 67:1491-1497.
46. Reed B., et al. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014, 71:195-200.
47. Kuriyama M., et al. Low levels of serum apolipoprotein A I and A II in senile dementia. Jpn. J. Psychiatry Neurol. 1994, 48:589-593.
48. Kawano M., et al. Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin. Chim. Acta 1995, 239:209-211.
49. Hye A., et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement. 2014, 10.1016/j.jalz.2014.05.1749.
50. Lewis T.L., et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J. Biol. Chem. 2010, 285:36958-36968.
51. Lefterov I., et al. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J. Biol. Chem. 2010, 285:36945-36957.
52. Krause B.R., Remaley A.T. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr. Opin. Lipidol. 2013, 24:480-486.
53. Leman L.J., Maryanoff B.E., Ghadiri M.R. Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J. Med. Chem. 2014, 57:2169-2196.
54. Kingwell B.A., Chapman M.J., Kontush A., Miller N.E. HDL-targeted therapies: progress, failures and future. Nat. Rev. Drug Discov. 2014, 13:445-464.
55. Lerch P.G., Fortsch V., Hodler G., Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 1996, 71:155-164.
56. Tardif J.C., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682.
57. Shaw J.A., et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 2008, 103:1084-1091.
58. Calkin A.C., et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009, 120:2095-2104.
59. Patel S., et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol. 2009, 53:962-971.
60. Chen Z., et al. Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice. J. Cardiovasc. Pharmacol. Ther. 2012, 17:315-323.
61. De Nardo D., et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat. Immunol. 2014, 15:152-160.
62. Wu B.J., et al. Inhibition of arthritis in the Lewis rat by apolipoprotein A-I and reconstituted high-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 2014, 34:543-551.
63. Stukas S., et al. The LXR agonist GW3965 increases apoA-I protein levels in the central nervous system independent of ABCA1. Biochim. Biophys. Acta 2012, 1821:536-546.
64. Stukas S., et al. LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice. J. Lipid Res. 2014, 10.1194/jlr.M049940.
65. Han B.H., et al. Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. Mol. Neurodegener. 2011, 6:86.
66. Shah A.S., Tan L., Lu L., J., Davidson W.S. The proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 2013, 10.1194/jlr.R035725.
67. Handattu S.P., et al. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2009, 34:525-534.